Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators.
about
Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolismDuration of treatment with vitamin K antagonists in symptomatic venous thromboembolismAntithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesManagement of Venous Thromboembolisms: Part I. The Consensus for Deep Vein ThrombosisVenous thromboembolism: Predicting recurrence and the need for extended anticoagulationRecurrent venous thromboembolism: what is the risk and how to prevent itMajor bleeding during secondary prevention of venous thromboembolism in patients who have completed anticoagulation: a systematic review and meta-analysisPredicting the risk of venous thromboembolism recurrenceThe epidemiology of venous thromboembolismGuidance for the treatment of deep vein thrombosis and pulmonary embolismDuration of anticoagulation for venous thromboembolic eventsExtended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-AnalysisUnresolved issues in anticoagulant therapyGuidelines on oral anticoagulation with warfarin - fourth editionReview of venous thromboembolism and race: the generalizability of treatment guidelines for high-risk populations.Risk of recurrence after a first unprovoked venous thromboembolism: external validation of the Vienna Prediction Model with pooled individual patient data.Latest medical treatment strategies for venous thromboembolism.Pitfalls in the Use of Anticoagulants.Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic reviewResidual vein obstruction as a predictor for recurrent thromboembolic events after a first unprovoked episode: data from the REVERSE cohort study.Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trialsDuration of treatment with vitamin K antagonists in symptomatic venous thromboembolism.Long-term survival after venous thromboembolism: a retrospective selected cohort study among young women.Evaluating patient values and preferences for thromboprophylaxis decision making during pregnancy: a study protocol.Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis.Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysisTrial Protocol: a randomised controlled trial of extended anticoagulation treatment versus routine anticoagulation treatment for the prevention of recurrent VTE and post thrombotic syndrome in patients being treated for a first episode of unprovokedPhysician compliance with outpatient oral anticoagulant guidelines in Auvergne, France.Oral heparin: status reviewCurrent pharmacotherapeutic options for treating deep vein thrombosis.Hypercoagulable state testing and malignancy screening following venous thromboembolic events.Management of thrombophilia.Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants.Optimal duration of anticoagulation in patients with venous thromboembolism.British Thoracic Society guidelines for the management of suspected acute pulmonary embolismDifferent Finite Durations of Anticoagulation and Outcomes following Idiopathic Venous Thromboembolism: A Meta-Analysis.Duration of anticoagulant therapy after initial idiopathic venous thromboembolism.Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial.Bleeding profiles of anticoagulants, including the novel oral direct thrombin inhibitor ximelagatran: definitions, incidence and management.Systemic thrombolysis in the upper extremity deep vein thrombosis.
P2860
Q24194466-247AC711-C7F0-4912-B503-9ACFE9231977Q24244786-C551E304-8646-45AA-BBA8-6C74D5F29618Q24633053-2FB929C4-FC73-4538-A412-CDDA6B3E6696Q26749273-44D3F3AC-E1DD-42CD-9E03-CA6669880751Q26825608-8BD5932D-687D-4A32-8D72-35871EEBC502Q26826847-CDB0785D-B5E2-48BD-A8D5-C66C2B0D4FD7Q26828750-E0E35E7F-498B-4FBD-8002-DD4689E6F4C7Q26865059-3F5B556A-E3D3-463B-8D66-2FC7A8F001EDQ28067893-05EF3BF8-55A5-443D-B46C-3686432DC257Q28078989-0346470C-0196-46B0-85DC-E3D93D454EB7Q28081375-D6B16B4B-E498-4C4E-8A13-51D1F3D07AD6Q28081717-498543C8-EADC-4FBF-A520-D282AD2C70DCQ28196778-8EEE59EB-2900-47F3-A13D-52423FCFEA3AQ28240666-604A8546-DF0B-485F-8C89-DA29612A575FQ30251792-43A0F56F-A2CC-44A5-AE53-9C83D4FC60F3Q30889099-7F0B3F86-6B9E-4A89-8EAE-C0D455BA598FQ33375535-E863F571-DF6D-4D24-9DA4-7029D469878CQ33441493-15547534-4F81-4EE1-919D-41A05F51E76EQ33795571-0EE2D2E0-A101-4830-8AD3-3BE0A409A10AQ33821311-C9BF8AAF-A706-4061-B8EB-3C851CF534DCQ33910755-4643089F-BBCE-4688-93C8-7E71C08EDE84Q33978357-DA6DB5C7-1F70-40D0-875D-3AB6E805C6AEQ34032280-60C69956-03CC-4D37-8BA4-89902403A0D8Q34286102-0C94DF9A-F1E2-4915-8291-B247A342E3FCQ34437785-7759071C-5658-473C-90E0-BF05BD2A8E7FQ34603112-097815EC-3875-4F0C-8A65-0AA17FA4056BQ34623435-5F9805D2-4042-4E5D-9669-ECD1D7F9D08FQ34742633-E1FB02AB-DC58-46EC-A8BC-C01E75F08854Q34893606-1E223C95-6E81-4693-B25E-C517075BE691Q35040760-560C8F5D-AAFF-4359-98BC-1A68664EA071Q35179215-4236E948-4F12-467F-9F3D-1531932E20EBQ35181607-669B6BFD-D729-40F6-9D8C-015941DEAB7BQ35206751-747C50C1-4FE5-4A43-B00D-AE2BA9E1F502Q35210139-9148926C-A2E9-44A1-BA36-911033D03926Q35535961-10325BEE-8806-4E0F-ADCF-F65EAE05F2DBQ35536251-EAD768C2-78D7-486C-BE63-A1E86033349BQ35547228-786B0695-79D6-4E7F-918F-B3D5103B7A06Q35724847-F578F4E8-9824-47F9-A41C-3EF513659356Q35878355-373C8AE9-91BF-4843-824F-7DE40F915118Q35945259-ED43BDC5-2F21-482B-856A-825B3DC27669
P2860
Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Three months versus one year o ...... n Italian Trial Investigators.
@en
Three months versus one year o ...... n Italian Trial Investigators.
@nl
type
label
Three months versus one year o ...... n Italian Trial Investigators.
@en
Three months versus one year o ...... n Italian Trial Investigators.
@nl
prefLabel
Three months versus one year o ...... n Italian Trial Investigators.
@en
Three months versus one year o ...... n Italian Trial Investigators.
@nl
P2093
P921
P1476
Three months versus one year o ...... n Italian Trial Investigators.
@en
P2093
A Bertoldi
G Guazzaloca
G Scannapieco
M G Santamaria
P Bagatella
P Prandoni
P304
P356
10.1056/NEJM200107193450302
P407
P577
2001-07-01T00:00:00Z